Trial Profile
A Prospective, Randomized Controlled Study to Compare the Efficacy and Safety of Baricitinib Combined With Glucocorticoid and Glucocorticoid Monotherapy in Proliferative IgG4-RD Patients With Eosinophilia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Prednisolone
- Indications Eosinophilia
- Focus Pharmacodynamics
- 28 Mar 2023 New trial record